The Food and Drug Administration on Tuesday cleared bemotrizinol for the U.S. sunscreen market, making it the first new sun-protection ingredient approved in this country in more than a quarter century. European regulators approved the same ingredient in 1999.
That gap, 26 years between European authorization and American clearance, tells you nearly everything you need to know about the FDA's capacity to move at the speed of modern science. A compound that billions of people overseas have been using safely for decades sat in a U.S. regulatory queue while American consumers were stuck with the same formulations their parents used.
The Dutch manufacturer DSM Nutritional Products plans to sell bemotrizinol under the brand name Parsol Shield later this year. The company will hold an 18-month exclusivity window before other manufacturers can use the ingredient, the Associated Press reported.
DSM first filed bemotrizinol with the FDA for review in 2005. That means the ingredient spent roughly two decades winding through the agency's approval process before reaching American shelves. For context, an entire generation of children grew up, graduated high school, and entered the workforce in the time it took federal regulators to say yes to a sunscreen compound already in wide use abroad.
The FDA says bemotrizinol met agency standards for protecting skin from ultraviolet rays while causing little irritation or absorption into the skin. The agency declared it safe for adults and children six months and older.
Bemotrizinol is the first ingredient to move through a streamlined approval process that Congress authorized in 2020 for updating lists of safe nonprescription drug ingredients. The fact that Congress had to intervene at all, creating a special fast track just to get over-the-counter products reviewed in less than geological time, speaks to the depth of the problem.
The full arc of this story is worth laying out. European authorities cleared bemotrizinol in 1999. Six years later, in 2005, the manufacturer filed for FDA review. The agency did not act.
In 2011, the FDA got around to banning misleading terms like "waterproof" on sunscreen labels and required that all sunscreens filter both UVA and UVB rays. Bemotrizinol still waited.
In 2020, Congress stepped in to create the streamlined process. In 2021, the FDA proposed additional measures, capping SPF numbers and requiring stronger UVA protection, but never completed them. And only now, in 2025, did bemotrizinol finally cross the finish line.
Twenty years from filing to approval. For a sunscreen ingredient.
The Environmental Working Group, which has long pushed the FDA to tighten sunscreen standards and allow new ingredients on the market, welcomed the decision. David Andrews of the group put it plainly:
"For decades, Americans have used outdated sunscreen tech while the rest of the world moved forward. The approval of bemotrizinol will help change that."
Andrews is not wrong on the facts. While American consumers were limited to the same set of UV filters approved before the turn of the century, sunscreen makers in Europe and other parts of the world had access to newer, more effective ingredients, bemotrizinol among them.
Dr. Mike Davis, acting director of the FDA's drug center, framed the approval as a commitment to consumer access:
"The FDA is committed to ensuring the American consumer has access to the most effective and safe therapies, including over-the-counter products like sunscreens."
That commitment, measured by the calendar, took two decades to deliver on a single ingredient.
This is not a story about sunscreen alone. It is a case study in what happens when a federal agency operates without meaningful accountability for speed. The FDA's mission includes protecting public health, but protection cuts both ways. Keeping a safe, effective product off the market for 20 years is its own form of harm, not through action, but through inaction.
Congress recognized the bottleneck in 2020 and built a workaround. Bemotrizinol is the first product to use that workaround. The question now is whether the streamlined process will actually produce results at scale, or whether it will become another layer of procedure that still takes years to navigate.
The FDA's own track record on sunscreen regulation offers little reassurance. The agency proposed stronger UVA standards and SPF caps in 2021. Four years later, those proposals remain incomplete. No final rule. No enforcement. Just a proposal sitting in a drawer.
Parsol Shield is expected to launch later this year. After the 18-month exclusivity period expires, other sunscreen manufacturers will be able to incorporate bemotrizinol into their products. That could eventually mean broader UVA protection across the American sunscreen market, something consumers in Europe have had access to since Bill Clinton's second term.
The broader question is whether this approval signals a genuine shift at the FDA or whether it is a one-off win that took an act of Congress to achieve. The agency still has unfinished business on sunscreen labeling, SPF standards, and UVA requirements. None of that work has been completed.
For American families heading into summer, the practical reality is simple: the same sunscreen options that existed last year will exist this year, with one new ingredient arriving sometime later. Real competition won't begin until the exclusivity window closes.
When a bureaucracy takes longer to approve a sunscreen ingredient than it took to put a man on the moon, the problem is not the science. It is the system.
